Drug Trial Radar · NCT07947056
A Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,500
Planned (sponsor's estimate)
Start
Jun 6, 2026
Primary completion
Dec 2028
Study completion Dec 2029
Sponsor
- Lead sponsor
- Tuberculosis Research Centre, IndiaGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Nov 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 14 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multi-centric RCT across 15 sites in India, tries to evaluates two strategies in order to improve treatment outcomes and reduce recurrences among persons with drug sensitive pulmonary TB (i) Usage of High dose Rifampicin (25mg/kg) given either for 2 months or for 6 months along with other first line anti-TB drugs (ii) Addition of a Fluoroquinolone along with high dose rifampicin to reduce the treatment duration from 6 months to 4 months.
Conditions
- Tuberculosis, Pulmonary, Drug Sensitive
Interventions
Standard 6-month treatment regimenDrug
Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol and Four months of Rifampicin, Isoniazid, and Ethambutol
High dose Rifampicin (25mg/Kg)Drug
Usage of High dose Rifampicin given for 2 months (only during Intensive Phase) along with other first line anti-TB drugs.
High dose Rifampicin (25mg/Kg)Drug
Usage of High dose Rifampicin given for 6 months (Both Intensive and Continuation Phase) along with other first line anti-TB drugs.
High dose Rifamipicn (25mg/Kg) & LevofloxacinDrug
Usage of High dose Rifampicin and Levofloxacin for 4 months along with other first line anti-TB drugs.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients cured and disease (recurrence) free and alive at 18 months post randomizationTime frame: Cure - At End of Treatment (4 or 6 months) & Recurrence - At 18 months post randomization
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
All India Institute of Medical Sciences(AIIMS), Mangalagiri
Guntur, Andhra Pradesh, India · Recruiting
All India Institute of Medical Sciences, Guwahati
Guwahati, Assam, India · Active not recruiting
Govt. PDU Medical College
Rajkot, Gujarat, India · Not yet recruiting
Govt. Medical College and NCH
Surat, Gujarat, India · Active not recruiting
Grant Govt. Medical College & Sir JJ Group of Hospitals
Mumbai, Maharashtra, India · Recruiting
All India Institute Of Medical Sciences, Nagpur
Nagpur, Maharashtra, India · Not yet recruiting
North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences (NEIGRIHMS)
Shillong, Meghālaya, India · Recruiting
National Institute of TB and Respiratory Diseases
New Delhi, National Capital Territory of Delhi, India · Not yet recruiting
Post Graduate Institute of Medical Education & Research, Capital Hospital
Bhubaneswar, Odisha, India · Active not recruiting
All India Institute of Medical Sciences (AIIMS), Bhubaneswar
Bhubaneswar, Odisha, India · Active not recruiting
ICMR - National Institute for Research in Tuberculosis
Chennai, Tamil Nadu, India · Recruiting
Govt. General and Chest Hospital, Osmania Medical College
Hyderabad, Telangana, India · Recruiting
Sarojini Naidu Medical College
Agra, Uttar Pradesh, India · Recruiting
Moti Lal Nehru Medical College
Allahābād, Uttar Pradesh, India · Recruiting
King George Medical University
Lucknow, Uttar Pradesh, India · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.